Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab
a retrospective observational study
Keywords:
COVID-19, Cytokine release syndrome, Mortality, Interleukins, Neutrophils, LymphocytesAbstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) can cause cytokine release syndrome (CRS), which leads to high mortality rates. Tocilizumab suppresses CRS by blocking the signal transduction of interleukin-6 (IL-6). OBJECTIVE: To evaluate the clinical and laboratory parameters associated with mortality among patients receiving tocilizumab treatment. DESIGN AND SETTING: Retrospective observational study conducted in the chest disease departments of two different training and research hospitals in the center of Ankara, Turkey. METHODS: Patients who were hospitalized and treated with tocilizumab in September 2020 were retro-spectively analyzed. Their laboratory parameters and clinical characteristics were obtained from the hospital information system database. Comparative analyses were performed between the patients who died and the ones who survived. RESULTS: A total of 58 patients who received tocilizumab treatment were included in this study, among whom 35 (60.3%) died. There was no difference between the mortality and survival groups in terms of white blood cell (WBC), neutrophil, lymphocyte, ferritin or C-reactive protein (CRP) levels detected on admission. WBC, lymphocyte, neutrophil and CRP levels measured on the third and fifth days after tocilizumab administration were found to be significantly lower in the survival group (P < 0.05). In multiple logistic regression analysis, age and oxygen saturation were determined to be independent risk factors for mortality. CONCLUSION: Persistently high WBC, CRP and neutrophil levels and low lymphocyte levels could be considered to be valuable indicators of mortality among COVID-19 patients treated with tocilizumab. Age and low oxygen saturation are independent risk factors for mortality among patients receiving tocilizumab treatment.
Downloads
References
Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020;323(8):709-10. PMID: 31999307; https://doi.org/10.1001/jama.2020.1097.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. PMID: 32007143; https://doi.org/10.1016/S0140-6736(20)30211-7.
Gupta S, Hayek SS, Wang W, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436-47. PMID: 32667668; https://doi.org/10.1001/jamainternmed.2020.3596. Erratum in: JAMA Intern Med. 2020;180(11):1555. Erratum in: JAMA Intern Med. 2021;181(8):1144.
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. PMID: 32085846; https://doi.org/10.1016/S2213-2600(20)30076-X. Erratum in: Lancet Respir Med. 2020.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. PMID: 29907163; https://doi.org/10.1186/s40425-018-0343-9.
Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739-48. PMID: 29808007; https://doi.org/10.1038/s41591-018-0036-4.
Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517-28. PMID: 28555385; https://doi.org/10.1007/s00281-017-0639-8.
Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448-57. PMID: 25898198; https://doi.org/10.1038/ni.3153. Erratum in: Nat Immunol. 2017;18(11):1271.
Navarro G, Taroumian S, Barroso N, Duan L, Furst D. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum. 2014;43(4):458-69. PMID: 24262929; https://doi.org/10.1016/j.semarthrit.2013.08.001.
Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(3):818-25. PMID: 15751095; https://doi.org/10.1002/art.20944.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. PMID: 32091533; https://doi.org/10.1001/jama.2020.2648.
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970-5. PMID: 32350134; https://doi.org/10.1073/pnas.2005615117.
Gupta S, Wang W, Hayek SS, et al. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern Med. 2021;181(1):41-51. PMID: 33080002; https://doi.org/10.1001/jamainternmed.2020.6252. Erratum in: JAMA Intern Med. 2021;181(4):570.
Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021;384(16):1503-16. PMID: 33631066; https://doi.org/10.1056/NEJMoa2028700.
Kow CS, Hasan SS. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2021;77(8):1089-94. PMID: 33378357; https://doi.org/10.1007/s00228-021-03087-z.
Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65(5):533-46. PMID: 32451563; https://doi.org/10.1007/s00038-020-01390-7.
Republic of Turkey, Ministry of Health, Directorate General of Public Health. COVID-19 (SARS-CoV-2 Infection) Guide. Study of Scientific Board. Ankara: Republic of Turkey, Ministry of Health; 2020 Available from: https://hsgm.saglik.gov.tr/depo/birimler/goc_sagligi/covid19/rehber/COVID-19_Rehberi20200414_eng_v4_002_14.05.2020.pdf Accessed in 2022 (May 27).
Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6:4. PMID: 29387417; https://doi.org/10.1186/s40364-018-0116-0.
Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-18. PMID: 23527958; https://doi.org/10.1056/NEJMoa1215134.
Fadel R, Morrison AR, Vahia A, et al. Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19. Clin Infect Dis. 2020;71(16):2114-20. PMID: 32427279; https://doi.org/10.1093/cid/ciaa601.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-8. PMID: 32125452; https://doi.org/10.1007/s00134-020-05991-x. Erratum in: Intensive Care Med. 2020.
Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814-8. PMID: 32253759; https://doi.org/10.1002/jmv.25801.
Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020;38(3):529-32. PMID: 32359035.
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. PMID: 32031570; https://doi.org/10.1001/jama.2020.1585.
Zhao M, Lu J, Tang Y, et al. Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies. Eur J Clin Pharmacol. 2021;77(3):311-9. PMID: 33051695; https://doi.org/10.1007/s00228-020-03017-5.
Sarhan RM, Madney YM, Abou Warda AE, Boshra MS. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab. Int J Clin Pract. 2021;75(6):e14079. PMID: 33550688; https://doi.org/10.1111/ijcp.14079.
